Clinical Trial Update: Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of atezolizumab and bevacizumab in recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Centre Leon Berard | Conditions: Head and Neck Neoplasms | Phase 2 | Status: COMPLETED